Export
The link always opens the latest version of this page.
Ask an AI about it
Open in ChatGPTA new chat that reads this entry from the site Open in ClaudeThe same, in ClaudeShare the link instead of a file, and they will always see the latest version.
Files are a snapshot of today. The live page has anything newer.
Lipfendra
First oral PCSK9 inhibitor approved by FDA for reducing LDL cholesterol in adults with hypercholesterolemia
- Category
- PCSK9 inhibitor 1 source
Lipfendra is an oral PCSK9 inhibitor and the first oral formulation of this drug class 1. Manufactured by Merck 2, it received FDA approval as a once-daily tablet for reducing LDL cholesterol in adults with hypercholesterolemia 2.
Clinical efficacy was demonstrated in two randomized controlled trials enrolling 3,207 adults with hypercholesterolemia 1. In the ASCVD trial, Lipfendra achieved a 56% reduction in LDL-C, while the HeFH trial showed a 59% reduction at Week 24 1. Overall, the drug reduces LDL cholesterol by an average of nearly 60% in patients with hypercholesterolemia 2.
Adverse reactions observed in the HeFH trial included diarrhea and dizziness, which occurred more frequently than in the placebo group 1.
Facts 2
| Attribute | Value | Confidence | Sources | Cited |
|---|---|---|---|---|
| Vendor | Merck | low | 1 | 2 |
| Category | PCSK9 inhibitor | low | 1 | 2 |
Platform 3
Neighbourhood
Developed by 2
Superseded by 1
Supersedes 1
Official links
Frequently mentioned together 5
Sources 2
- FDA approves new kind of cholesterol pill · Hacker News (YC)
- Once-daily LDL cholesterol-smashing pill gets FDA approval · New Atlas